These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28967552)

  • 21. Clinical Trials Referral Resource. Clinical trials in bladder and urothelial cancers.
    Kaplan RS; Cheson BD; Nelson AP
    Oncology (Williston Park); 1997 Sep; 11(9):1348, 1351. PubMed ID: 9306423
    [No Abstract]   [Full Text] [Related]  

  • 22. Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies?
    Tonyali S; Yazici S
    Int Urol Nephrol; 2016 May; 48(5):671-80. PubMed ID: 26843415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re: Clonal Evolution of Chemotherapy-resistant Urothelial Carcinoma.
    Junker K; Ohlmann CH
    Eur Urol; 2017 Aug; 72(2):316-317. PubMed ID: 28341322
    [No Abstract]   [Full Text] [Related]  

  • 24. Re: Clonal Evolution of Chemotherapy-resistant Urothelial Carcinoma.
    Black PC
    Eur Urol; 2017 Oct; 72(4):653-654. PubMed ID: 28583313
    [No Abstract]   [Full Text] [Related]  

  • 25. Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to Select.
    Drake CG; Bivalacqua TJ; Hahn NM
    J Clin Oncol; 2016 Sep; 34(26):3115-6. PubMed ID: 27458310
    [No Abstract]   [Full Text] [Related]  

  • 26. Expanding Immunotherapy Options for Bladder Cancer: Commentary on: Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
    Lavoie JM; Bidnur S; Black PC; Eigl BJ
    Urology; 2017 Aug; 106():1-2. PubMed ID: 28454987
    [No Abstract]   [Full Text] [Related]  

  • 27. First findings of gap junction proteins in human urothelial carcinoma.
    Comberg D; Gauer A; Tschernig T
    World J Urol; 2016 Jan; 34(1):145-7. PubMed ID: 26511750
    [No Abstract]   [Full Text] [Related]  

  • 28. [The pathologist at the core of the new classification for urothelial carcinomas].
    Molinié V
    Ann Pathol; 2016 Aug; 36(4):233-4. PubMed ID: 27521982
    [No Abstract]   [Full Text] [Related]  

  • 29. [Urothelial carcinoma: immuno-oncology on all fronts].
    Grüllich C; Kübler H
    Urologe A; 2020 Jul; 59(7):783. PubMed ID: 32617625
    [No Abstract]   [Full Text] [Related]  

  • 30. Re: Molecular Classification of Urothelial Carcinoma: Global mRNA Classification Versus Tumour-cell Phenotype Classification.
    Peeker R
    Eur Urol; 2018 May; 73(5):809-810. PubMed ID: 29273405
    [No Abstract]   [Full Text] [Related]  

  • 31. Re: Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis from the National Cancer Data Base.
    Mathieu R; Peyronnet B; Bensalah K
    Eur Urol; 2016 Nov; 70(5):894. PubMed ID: 27497763
    [No Abstract]   [Full Text] [Related]  

  • 32. Re: Efficacy of High-intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis from the National Cancer Data Base.
    Woldu SL; Lotan Y
    Eur Urol; 2016 Nov; 70(5):893. PubMed ID: 27498598
    [No Abstract]   [Full Text] [Related]  

  • 33. [Subsequent upper urothelial cancer following bladder tumor].
    Kuruma H; Ao T; Murayama M; Mizoguchi H; Koshiba K
    Hinyokika Kiyo; 2002 Apr; 48(4):199-202. PubMed ID: 12048930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re: Comprehensive Genomic Profiling of 295 Cases of Clinically Advanced Urothelial Carcinoma of the Urinary Bladder Reveals a High Frequency of Clinically Relevant Genomic Alterations.
    Chang SS
    J Urol; 2017 Feb; 197(2):319. PubMed ID: 28093142
    [No Abstract]   [Full Text] [Related]  

  • 35. Re: Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3 Trial.
    Sonpavde G; Pal S
    Eur Urol; 2016 Jul; 70(1):203. PubMed ID: 27302289
    [No Abstract]   [Full Text] [Related]  

  • 36. The Cancer Immunogram: A Pledge for a Comprehensive Biomarker Approach for Personalized Immunotherapy in Urothelial Cancer.
    Zahoor H; Grivas P
    Eur Urol; 2019 Mar; 75(3):445-447. PubMed ID: 30558899
    [No Abstract]   [Full Text] [Related]  

  • 37. Re: Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol 2019;75:423-32.
    Eriksson P; Sjödahl G
    Eur Urol; 2019 Apr; 75(4):e106-e107. PubMed ID: 30522915
    [No Abstract]   [Full Text] [Related]  

  • 38. The application of hematopoietic growth factors in advanced transitional cell carcinoma of the urinary tract.
    de Mulder PH; Sternberg CN; van Oosterom AT; Fossa SD
    Semin Oncol; 1994 Feb; 21(1 Suppl 1):65-9. PubMed ID: 7512278
    [No Abstract]   [Full Text] [Related]  

  • 39. Independent predictors of metachronous bladder transitional cell carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract.
    Chung SD
    BJU Int; 2008 Aug; 102(4):518; author reply 518-9. PubMed ID: 18699961
    [No Abstract]   [Full Text] [Related]  

  • 40. [Non-urothelial tumors of the urinary tract].
    Mikuz G
    Verh Dtsch Ges Pathol; 1993; 77():180-98. PubMed ID: 7511278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.